Skip to main content

Table 2 Antifungal susceptibility testing of various Candida spp.

From: Isolation, speciation and antifungal susceptibility testing of Candida isolates from various clinical specimens at a tertiary care hospital, Nepal

Antifungal agents

Candida spp.

Total (N = 100)

C. albicans (N = 56)

C. tropicalis (N = 20)

C. krusei (N = 10)

C. glabrata (N = 14)

Ketoconazole

 S

4 (7.2%)

0 (0%)

2 (20%)

0 (0%)

6 (6%)

 SDD

2 (3.6%)

4 (20%)

0 (0%)

2 (14.3%)

8 (8%)

 R

50 (89.3%)

16 (80%)

8 (80%)

12 (85.8%)

86 (86%)

Fluconazole

 S

40 (71.5%)

12 (60%)

4 (40%)

8 (57.2%)

64 (64%)

 SDD

6 (10.8%)

4 (20%)

6 (60%)

0 (0%)

16 (16%)

 R

10 (17.9%)

4 (20%)

0 (0%)

6 (42.9%)

20 (20%)

Miconazole

 S

30 (53.6%)

10 (50%)

2 (20%)

2 (14.2%)

44 (44%)

 SDD

18 (32.2%)

8 (40%)

6 (60%)

12 (85.8%)

44 (44%)

 R

8 (14.3%)

2 (10%)

2 (20%)

0 (0%)

12 (12%)

Clotrimazole

 S

44 (78.6%)

16 (80%)

10 (100%)

12 (85.8%)

82 (82%)

 SDD

8 (14.3%)

4 (20%)

0 (0%)

0 (0%)

16 (16%)

 R

4 (7.2%)

0 (0%)

0 (0%)

2 (14.2%)

6 (6%)